-
Posted by
Two Blokes Jun 13 -
Filed in
Stock
-
8 views
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center in New York City as part of its ongoing Phase 2 clinical trial of intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Weill Cornell marks the fifth site participating in the trial, joining Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.
